Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.
Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute
Advertisement
Articles by Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute
Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.
Shared insight on updates in the chronic myeloid leukemia treatment landscape following the ASH 2021 annual meeting.
Expert perspectives on clinical data readouts in acute lymphocytic leukemia from the ASH 2021 annual meeting.
Advertisement
Latest Updated Articles
Rapid Readouts: Five-Year Analysis of MURANO StudyPublished: December 23rd 2020 | Updated:
Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO StudyPublished: January 18th 2021 | Updated:
ASH 2021: Novel Therapy in Acute Lymphocytic LeukemiaPublished: January 31st 2022 | Updated:
ASH 2020 Updates in Relapsed/Refractory B-Cell LymphomasPublished: January 22nd 2021 | Updated:
ASH 2020 Updates in CLLPublished: January 22nd 2021 | Updated:
ASH 2020 Updates in Non-CLL B-Cell LymphomasPublished: January 22nd 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5